Skip to main content
. Author manuscript; available in PMC: 2022 Jun 15.
Published in final edited form as: Nature. 2021 Dec 15;600(7890):727–730. doi: 10.1038/s41586-021-04161-3

Extended Data Table 1.

Follow-up duration calculated as time from randomization to the date of death or the database cutoff date, whichever was earliest

Follow-up duration Pembrolizumab group Placebo group

Intention-to-treat population N=217 N=217
 Median,* months 8.4 7.7
 Range, months 0.1–19.0 0.5–17.9
Efficacy population N=133 N=131
 Median,* months 11.1 10.4
 Range, months 2.2–19.0 0.5–17.9
*

Medians were calculated using the observation time method.